Estrogen receptor beta expression in invasive breast cancer

Sherri Mann, Rodolfo Laucirica, Nicole Carlson, Pamela S. Younes, Najeeba Ali, Anas Younes, Yang Li, Mamoun Younes

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

The aim of this work was to determine the extent of estrogen receptor beta (ER-β) expression in invasive breast cancer (BrCA) and whether ER-β expression is correlated with response to adjuvant hormonal therapy with tamoxifen (AHTT). Immunohistochemical staining (IHC) for estrogen receptor alpha (ER-α) and ER-β was performed on sections of formalin-fixed and paraffin-embedded tissue from 47 unselected invasive breast carcinomas (BrCA). IHC for ER-β was also performed on sections of BrCA from 118 women who were treated with mastectomy and AHTT. Survival analysis was performed using the Kaplan-Meier method and the log-rank test. Of the 47 unselected BrCA, 17 (36%) were negative for ER-α and of these, 8 (47% of ER-α negative cases and 17% of all 47 patients) were ER-β positive. Five of the 8 ER-α negative and ER-β positive cases were positive for ER biochemically. There was no correlation between ER-β positivity and overall survival in the unselected group. By contrast, in the group of women treated with AHTT, expression of ER-β in more than 10% of cancer cells was associated with better survival (P = .0077), even in women with node-negative BrCA (P = .0069). In conclusion, our results show that a significant number of women with BrCA are positive for ER-β only, and may be determined to be ER-negative when currently available IHC is used. ER-β status is a significant predictor of response to AHTT in women with BrCA. Larger studies with multivariate analysis are needed to confirm these findings.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalHuman pathology
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Estrogen Receptor beta
Breast Neoplasms
Tamoxifen
Staining and Labeling
Survival
Estrogen Receptor alpha
Mastectomy
Therapeutics
Survival Analysis
Paraffin
Formaldehyde

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Mann, S., Laucirica, R., Carlson, N., Younes, P. S., Ali, N., Younes, A., ... Younes, M. (2001). Estrogen receptor beta expression in invasive breast cancer. Human pathology, 32(1), 113-118. https://doi.org/10.1053/hupa.2001.21506

Estrogen receptor beta expression in invasive breast cancer. / Mann, Sherri; Laucirica, Rodolfo; Carlson, Nicole; Younes, Pamela S.; Ali, Najeeba; Younes, Anas; Li, Yang; Younes, Mamoun.

In: Human pathology, Vol. 32, No. 1, 01.01.2001, p. 113-118.

Research output: Contribution to journalArticle

Mann, S, Laucirica, R, Carlson, N, Younes, PS, Ali, N, Younes, A, Li, Y & Younes, M 2001, 'Estrogen receptor beta expression in invasive breast cancer', Human pathology, vol. 32, no. 1, pp. 113-118. https://doi.org/10.1053/hupa.2001.21506
Mann, Sherri ; Laucirica, Rodolfo ; Carlson, Nicole ; Younes, Pamela S. ; Ali, Najeeba ; Younes, Anas ; Li, Yang ; Younes, Mamoun. / Estrogen receptor beta expression in invasive breast cancer. In: Human pathology. 2001 ; Vol. 32, No. 1. pp. 113-118.
@article{d5f955dfaf4d455793bd97a90ea898b1,
title = "Estrogen receptor beta expression in invasive breast cancer",
abstract = "The aim of this work was to determine the extent of estrogen receptor beta (ER-β) expression in invasive breast cancer (BrCA) and whether ER-β expression is correlated with response to adjuvant hormonal therapy with tamoxifen (AHTT). Immunohistochemical staining (IHC) for estrogen receptor alpha (ER-α) and ER-β was performed on sections of formalin-fixed and paraffin-embedded tissue from 47 unselected invasive breast carcinomas (BrCA). IHC for ER-β was also performed on sections of BrCA from 118 women who were treated with mastectomy and AHTT. Survival analysis was performed using the Kaplan-Meier method and the log-rank test. Of the 47 unselected BrCA, 17 (36{\%}) were negative for ER-α and of these, 8 (47{\%} of ER-α negative cases and 17{\%} of all 47 patients) were ER-β positive. Five of the 8 ER-α negative and ER-β positive cases were positive for ER biochemically. There was no correlation between ER-β positivity and overall survival in the unselected group. By contrast, in the group of women treated with AHTT, expression of ER-β in more than 10{\%} of cancer cells was associated with better survival (P = .0077), even in women with node-negative BrCA (P = .0069). In conclusion, our results show that a significant number of women with BrCA are positive for ER-β only, and may be determined to be ER-negative when currently available IHC is used. ER-β status is a significant predictor of response to AHTT in women with BrCA. Larger studies with multivariate analysis are needed to confirm these findings.",
author = "Sherri Mann and Rodolfo Laucirica and Nicole Carlson and Younes, {Pamela S.} and Najeeba Ali and Anas Younes and Yang Li and Mamoun Younes",
year = "2001",
month = "1",
day = "1",
doi = "10.1053/hupa.2001.21506",
language = "English (US)",
volume = "32",
pages = "113--118",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Estrogen receptor beta expression in invasive breast cancer

AU - Mann, Sherri

AU - Laucirica, Rodolfo

AU - Carlson, Nicole

AU - Younes, Pamela S.

AU - Ali, Najeeba

AU - Younes, Anas

AU - Li, Yang

AU - Younes, Mamoun

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The aim of this work was to determine the extent of estrogen receptor beta (ER-β) expression in invasive breast cancer (BrCA) and whether ER-β expression is correlated with response to adjuvant hormonal therapy with tamoxifen (AHTT). Immunohistochemical staining (IHC) for estrogen receptor alpha (ER-α) and ER-β was performed on sections of formalin-fixed and paraffin-embedded tissue from 47 unselected invasive breast carcinomas (BrCA). IHC for ER-β was also performed on sections of BrCA from 118 women who were treated with mastectomy and AHTT. Survival analysis was performed using the Kaplan-Meier method and the log-rank test. Of the 47 unselected BrCA, 17 (36%) were negative for ER-α and of these, 8 (47% of ER-α negative cases and 17% of all 47 patients) were ER-β positive. Five of the 8 ER-α negative and ER-β positive cases were positive for ER biochemically. There was no correlation between ER-β positivity and overall survival in the unselected group. By contrast, in the group of women treated with AHTT, expression of ER-β in more than 10% of cancer cells was associated with better survival (P = .0077), even in women with node-negative BrCA (P = .0069). In conclusion, our results show that a significant number of women with BrCA are positive for ER-β only, and may be determined to be ER-negative when currently available IHC is used. ER-β status is a significant predictor of response to AHTT in women with BrCA. Larger studies with multivariate analysis are needed to confirm these findings.

AB - The aim of this work was to determine the extent of estrogen receptor beta (ER-β) expression in invasive breast cancer (BrCA) and whether ER-β expression is correlated with response to adjuvant hormonal therapy with tamoxifen (AHTT). Immunohistochemical staining (IHC) for estrogen receptor alpha (ER-α) and ER-β was performed on sections of formalin-fixed and paraffin-embedded tissue from 47 unselected invasive breast carcinomas (BrCA). IHC for ER-β was also performed on sections of BrCA from 118 women who were treated with mastectomy and AHTT. Survival analysis was performed using the Kaplan-Meier method and the log-rank test. Of the 47 unselected BrCA, 17 (36%) were negative for ER-α and of these, 8 (47% of ER-α negative cases and 17% of all 47 patients) were ER-β positive. Five of the 8 ER-α negative and ER-β positive cases were positive for ER biochemically. There was no correlation between ER-β positivity and overall survival in the unselected group. By contrast, in the group of women treated with AHTT, expression of ER-β in more than 10% of cancer cells was associated with better survival (P = .0077), even in women with node-negative BrCA (P = .0069). In conclusion, our results show that a significant number of women with BrCA are positive for ER-β only, and may be determined to be ER-negative when currently available IHC is used. ER-β status is a significant predictor of response to AHTT in women with BrCA. Larger studies with multivariate analysis are needed to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=0035122520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035122520&partnerID=8YFLogxK

U2 - 10.1053/hupa.2001.21506

DO - 10.1053/hupa.2001.21506

M3 - Article

VL - 32

SP - 113

EP - 118

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 1

ER -